NEWS RELEASE
RESEARCH TRIANGLE PARK, N.C., January 7, 2008 - SCYNEXIS, Inc. announced today its participation in the 26th Annual JPMorgan Healthcare Conference, January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco. Yves J. Ribeill, Ph.D., President and CEO, will provide an overview of the Company and its programs in development at 11:30 a.m. PST on Tuesday, January 8, 2008 in the Elizabethan C/D room.
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. SCYNEXIS’ mission is to be the leader in delivering effective and innovative drug pipeline solutions to its pharmaceutical partners.
SCYNEXIS research teams integrate medicinal chemistry, advanced biological screening, computational chemistry, bioanalysis and analytical chemistry and use powerful, proprietary technologies such as the HEOS® Software Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to advance molecules to candidate selection. SCYNEXIS development teams have been tailored to be especially effective in moving customer projects from the discovery phase to the clinic. SCYNEXIS process chemistry and bioanalytical/DMPK departments operate under current GMP/GLP guidelines and have a strong track record of success. Our website is located at www.scynexis.com.
SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications
919-878-1144
rick@rickrountree.com
SCYNEXIS Investor Relations:
Douglas MacDougall
MacDougall Biomedical Communications
781-235-3060